Surface Oncology Inc (NASDAQ:SURF) saw a significant increase in short interest in the month of June. As of June 30th, there was short interest totalling 644,100 shares, an increase of 86.3% from the May 30th total of 345,800 shares. Based on an average daily volume of 72,200 shares, the days-to-cover ratio is presently 8.9 days. Currently, 5.9% of the company’s stock are short sold.

A number of research analysts recently issued reports on SURF shares. Cowen reiterated a “hold” rating on shares of PDL BioPharma in a report on Thursday, May 9th. Zacks Investment Research cut Haynes International from a “hold” rating to a “sell” rating in a research report on Wednesday, May 8th. Finally, ValuEngine cut Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st.

Shares of SURF stock opened at $2.64 on Friday. The stock’s fifty day moving average price is $3.25. Surface Oncology has a twelve month low of $2.47 and a twelve month high of $16.62. The company has a market cap of $70.72 million, a price-to-earnings ratio of -8.00 and a beta of 2.40. The company has a debt-to-equity ratio of 0.20, a current ratio of 11.28 and a quick ratio of 11.28.

Surface Oncology (NASDAQ:SURF) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.31. Surface Oncology had a negative return on equity of 38.97% and a negative net margin of 148.15%. The company had revenue of $14.43 million for the quarter, compared to the consensus estimate of $2.50 million. On average, sell-side analysts anticipate that Surface Oncology will post -1.97 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC bought a new position in shares of Surface Oncology in the fourth quarter valued at approximately $56,000. BlackRock Inc. lifted its position in shares of Surface Oncology by 82.5% during the fourth quarter. BlackRock Inc. now owns 1,097,041 shares of the company’s stock worth $4,651,000 after acquiring an additional 496,072 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Surface Oncology by 302.2% in the fourth quarter. Bank of New York Mellon Corp now owns 61,100 shares of the company’s stock worth $259,000 after buying an additional 45,910 shares in the last quarter. Northern Trust Corp raised its position in shares of Surface Oncology by 50.3% in the fourth quarter. Northern Trust Corp now owns 119,437 shares of the company’s stock worth $506,000 after buying an additional 39,964 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Surface Oncology by 50.5% in the fourth quarter. Geode Capital Management LLC now owns 116,745 shares of the company’s stock worth $494,000 after buying an additional 39,174 shares in the last quarter. 59.04% of the stock is owned by hedge funds and other institutional investors.

About Surface Oncology

Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27.

Recommended Story: The benefits and drawbacks of dollar cost averaging

Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.